Trials / Completed
CompletedNCT04221230
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 204 (actual)
- Sponsor
- Neumora Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMRA-335140 | Active Drug |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2020-01-03
- Primary completion
- 2022-04-08
- Completion
- 2022-06-23
- First posted
- 2020-01-09
- Last updated
- 2025-05-29
- Results posted
- 2025-05-29
Locations
38 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04221230. Inclusion in this directory is not an endorsement.